Paul Edward Klaver - Net Worth and Insider Trading

Paul Edward Klaver Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul Edward Klaver owns 1 companies in total, including Eloxx Pharmaceuticals Inc (ELOX) .

Click here to see the complete history of Paul Edward Klaver’s form 4 insider trades.

Insider Ownership Summary of Paul Edward Klaver

Ticker Comapny Transaction Date Type of Owner
ELOX Eloxx Pharmaceuticals Inc 2012-03-12 10 percent owner

Paul Edward Klaver Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Paul Edward Klaver Ownership Network

Ownership Network List of Paul Edward Klaver

No Data

Ownership Network Relation of Paul Edward Klaver

Insider Network Chart

Paul Edward Klaver Owned Company Details

What does Eloxx Pharmaceuticals Inc do?

Who are the key executives at Eloxx Pharmaceuticals Inc?

Paul Edward Klaver is the 10 percent owner of Eloxx Pharmaceuticals Inc. Other key executives at Eloxx Pharmaceuticals Inc include director & PRESIDENT AND CEO Sumit Aggarwal , HEAD OF R&D Vijay Modur , and Chief Financial Officer Daniel E. Geffken .

Eloxx Pharmaceuticals Inc (ELOX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eloxx Pharmaceuticals Inc (ELOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eloxx Pharmaceuticals Inc (ELOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eloxx Pharmaceuticals Inc (ELOX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Eloxx Pharmaceuticals Inc Insider Transactions

No Available Data

Paul Edward Klaver Mailing Address

Above is the net worth, insider trading, and ownership report for Paul Edward Klaver. You might contact Paul Edward Klaver via mailing address: 134 Columbia Street W., Unit 18, Waterloo A6 N2l 3k8.

Discussions on Paul Edward Klaver

No discussions yet.